Loading…
TransCode Therapeutics, Inc. is projected to decline to $4.80 by 2027, a -6% move from its current price of $5.09. RNAZ is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $4.90 | $5.09 | $5.29 | +0.01% |
| May 30 | $4.83 | $5.09 | $5.37 | +0.02% |
| May 31 | $4.77 | $5.09 | $5.44 | +0.03% |
| Jun 1 | $4.72 | $5.09 | $5.49 | +0.04% |
| Jun 2 | $4.68 | $5.09 | $5.54 | +0.05% |
| Jun 3 | $4.64 | $5.09 | $5.59 | +0.06% |
| Jun 4 | $4.61 | $5.09 | $5.63 | +0.07% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $4.61 | $5.09 | $5.63 | +0.07% |
| Week 2 | $4.42 | $5.10 | $5.87 | +0.15% |
| Week 3 | $4.29 | $5.10 | $6.07 | +0.22% |
| Week 4 | $4.18 | $5.10 | $6.24 | +0.29% |
| Week 5 | $4.08 | $5.11 | $6.39 | +0.37% |
| Week 6 | $4.00 | $5.11 | $6.53 | +0.44% |
| Week 7 | $3.93 | $5.12 | $6.67 | +0.52% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
TransCode Therapeutics, Inc. is a clinical-stage company that develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers. Its work focuses on therapies in oncology and RNA biology, with candidates including SEVIPROTIMUT-L for adjuvant treatment of Stage IIB and IIC melanoma that has completed Phase 2, and TTX-MC138 that targets microRNA-10b and has completed Phase 1.
The company also has preclinical programs such as TTX-siPDL1, TTX-RIGA, and TTX-siMYC, and is developing oncolytic virus therapy. TransCode has a strategic collaboration with The University of Texas M. D.
Anderson Cancer Center. The company was incorporated in 2016 and is based in Boston, Massachusetts.
RNAZ is the ticker for TransCode Therapeutics, Inc., which currently trades at $5.09 with a market capitalization of $4.84M and a market rank of 5289. The near term price picture is described as neutral, with the stock showing limited upside in the next few years according to the provided forecasts. The multi‑year view shows a path from a bearish 2030 with volatility but potential later upside through 2040 and 2050.
These figures are estimates and not guarantees.
A major floor 50.0% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
The nearest ceiling, 75.0% above — a clean break opens room to run.
A major ceiling 142.4% above — clearing it would confirm fresh momentum.
Key RNAZ support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of RNAZ market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $5.79 | Sell | $5.68 | Sell |
| MA 10 | $6.17 | Sell | $6.10 | Sell |
| MA 20 | $6.89 | Sell | $6.72 | Sell |
| MA 50 | $8.01 | Sell | $7.71 | Sell |
| MA 100 | $8.72 | Sell | $9.17 | Sell |
| MA 200 | $9.55 | Sell | $388.29 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 17.45 | Buy |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -160.81 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.13 | Sell |
| ROC (12) | -30.46 | Sell |
| Bollinger %B (20,2) | -0.01 | Buy |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -1.12 | Sell |
| Awesome (5,34) | -1.83 | Sell |
| Ultimate (7,14,28) | 10.98 | Buy |
| Momentum (10) | -1.64 | Sell |
| Aroon Osc (25) | -100.00 | Sell |
| Hull MA (9) | 5.48 | Sell |
| ADX (14) | 39.77 | Sell |
| ATR (14) | 0.23 | Info |
The 30-day technical picture shows neutral sentiment with RSI14 at 20, indicating weakness relative to common momentum thresholds. The stock trades around the moving averages, with SMA50 at $8.01 and SMA200 at $9.55. Support is noted at $5.09 and resistance at $8.91, framing the near term trading band.
The 30-day price range spans from $3.97 to $6.53, reflecting modest volatility in the interim.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $5.09 | $5.09 | $6.31 | 0% | Neutral | |
| $3.66 | $4.80 | $6.74 | -6% | Neutral | |
| $3.34 | $4.55 | $6.70 | -11% | Neutral | |
| $3.18 | $4.48 | $6.83 | -12% | Neutral | |
| $2.83 | $4.11 | $6.47 | -19% | Bearish | |
| $3.07 | $4.58 | $7.41 | -10% | Neutral | |
| $3.96 | $6.05 | $10.02 | +19% | Neutral | |
| $3.76 | $5.91 | $9.99 | +16% | Neutral | |
| $3.64 | $5.85 | $10.09 | +15% | Neutral | |
| $3.74 | $6.15 | $10.81 | +21% | Bullish | |
| $4.86 | $8.87 | $16.83 | +74% | Bullish | |
| $5.11 | $11.31 | $23.93 | +122% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $5.09 | $5.09 | $5.99 | +0.00% |
| June 2026 | $4.22 | $5.00 | $6.09 | -1.77% |
| July 2026 | $4.29 | $5.14 | $6.38 | +2.78% |
| August 2026 | $4.34 | $5.25 | $6.61 | +2.21% |
| September 2026 | $4.13 | $5.03 | $6.40 | -4.25% |
| October 2026 | $3.94 | $4.83 | $6.21 | -3.95% |
| November 2026 | $3.96 | $4.89 | $6.35 | +1.22% |
| December 2026 | $3.88 | $4.82 | $6.31 | -1.43% |
Click any year to see its month-by-month RNAZ forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, RNAZ is projected to trade between $5.09 and $6.31, averaging $5.09 — a potential gain of 0% from today's $5.09. Price action looks broadly range-bound.
TransCode Therapeutics, Inc.'s 2027 outlook centres on $4.80, within a $3.66 to $6.74 range. That is -6% versus the projected 2026 average. That marks a -6% change versus current levels. A consolidation phase looks the most probable path here.
By 2028, RNAZ could reach as high as $6.70, with a base case around $4.55 and support toward $3.34 — roughly -11% from $5.09. Price action looks broadly range-bound.
Expect RNAZ to range from $3.18 to $6.83 through 2029. The $4.48 average target implies a -12% move from current prices. That is -2% versus the projected 2028 average. A consolidation phase looks the most probable path here.
The RNAZ price prediction for 2030 points to an average of $4.11 (low $2.83, high $6.47) — a potential decline of -19% on today's $5.09. A cyclical pullback looks likely — prices rarely move in a straight line.
In 2031, RNAZ is projected to trade between $3.07 and $7.41, averaging $4.58 — a potential decline of -10% from today's $5.09. That is up +12% on the projected 2030 average. A consolidation phase looks the most probable path here.
TransCode Therapeutics, Inc.'s 2032 outlook centres on $6.05, within a $3.96 to $10.02 range. That is up +32% on the projected 2031 average. That marks a +19% change versus current levels. Price action looks broadly range-bound.
By 2033, RNAZ could reach as high as $9.99, with a base case around $5.91 and support toward $3.76 — roughly +16% from $5.09. A consolidation phase looks the most probable path here.
Expect RNAZ to range from $3.64 to $10.09 through 2034. The $5.85 average target implies a +15% move from current prices. That is -1% versus the projected 2033 average. Price action looks broadly range-bound.
The RNAZ price prediction for 2035 points to an average of $6.15 (low $3.74, high $10.81) — a potential gain of +21% on today's $5.09. Buyers look set to stay in control over this stretch.
In 2040, RNAZ is projected to trade between $4.86 and $16.83, averaging $8.87 — a potential gain of +74% from today's $5.09. That is up +44% on the projected 2035 average. Momentum favours further upside here.
TransCode Therapeutics, Inc.'s 2050 outlook centres on $11.31, within a $5.11 to $23.93 range. That is up +27% on the projected 2040 average. That marks a +122% change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in RNAZ today (≈ 196.463654 RNAZ) could be worth
$2,221.94
+$1,221.94 (+122%) by 2050 · US Dollar
Based on the average projected RNAZ price of $11.31 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in RNAZwould be worth at today's price.
$1,000 invested in RNAZ on May 27, 2025 (≈ 145.56041 RNAZ) would be worth
$740.9
-$259.1 (-25.9%) today · 0.74× · US Dollar
Based on a RNAZ entry price of $6.87 vs. today's $5.09.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $6.11 | $833.06 | -16.7% |
| 1 month ago | $8.52 | $597.42 | -40.3% |
| 3 months ago | $10.17 | $500.49 | -50.0% |
| 6 months ago | $9.29 | $547.9 | -45.2% |
| 1 year ago | $6.87 | $740.9 | -25.9% |
| All time (4.9y) ago | $2,956,800 | $0 | -100.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our RNAZ forecast.
Our base-case forecast reaches $10.00 around 2050.
Implied market cap at $10.00: $9.5M
The multi-year forecast begins with a bear signal in 2030, where the average price is projected at $4.11, the min at $2.83, the max at $6.47, and ROI at -19.3, with sentiment labeled BEARISH. Recovery is seen in later years, with 2032 showing an average of $6.05 and ROI 18.9, and 2035 an average of $6.15 with ROI 20.8 amid BEARISH to NEUTRAL shifts in sentiment leading into stronger upside. By 2040 the average rises to $8.87 with ROI 74.3 and a BULLISH sentiment, and by 2050 an average of $11.31 with ROI 122.2 and a BULLISH sentiment.
The max values climb to $16.83 in 2040 and to $23.93 in 2050, indicating meaningful upside potential if the longer-term trajectory plays out.
Tap a question to reveal the answer.
The 2030 forecast shows min $2.83, avg $4.11, max $6.47 with ROI -19.3 and sentiment BEARISH.
Near term, the 2026 forecast shows min $5.09, avg $5.09, max $6.31 with ROI 0 and sentiment NEUTRAL; later years show negative ROI (2030s) before stronger upside in the 2030s and into 2040/2050, reflecting mixed prospects.
Yes, the forecast shows instances where the max prices exceed $10, including $10.02 in 2032, $10.09 in 2034, and $10.81 in 2035, with higher upside in 2040 ($16.83 max) and 2050 ($23.93 max).
The 2050 forecast shows min $5.11, avg $11.31, max $23.93 with ROI 122.2 and sentiment BULLISH.
Annualized volatility is 70%, indicating substantial price dispersion over time.
TransCode Therapeutics, Inc. Community Discussion
0Share your TransCode Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.